Abstract:Susanna S. Park ^ Department of Ophthalmology & Vision Science, University of California Davis Eye Center, Sacramento, CA, USA ^ ORCID: 0000-0001-5911-6671. Comment on: Ding X, Sun Z, Guo Y, et al . Inhibition of NF-κB ameliorates aberrant retinal glia activation and inflammatory responses in streptozotocin-induced diabetic rats. Ann Transl Med 2023;11:197. Keywords: Diabetes; microglia; Muller cells; retinal neurodegeneration; vascular endothelial growth factor (VEGF) Submitted Mar 07, 2023. Accepted for publication Apr 30, 2023. Published online May 18, 2023. doi: 10.21037/atm-23-1166 Diabetic retinopathy (DR) is a leading cause of irreversible blindness in adults (1-3). Treatments available to limit vision loss from complications of DR include intravitreal injection of drugs that inhibit vascular endothelial growth factor (VEGF) or inflammation, surgery and retinal laser photocoagulation (3). Despite these interventions, blindness from DR persists since the retinal vasculopathy and neuronal degeneration cannot be reversed. Extensive research has been conducted to decipher the molecular pathways involved in the development of DR in the hopes of finding a cure. Oxidative stress and inflammation are important pathways activated in DR (3). Recent studies indicate that neurodegeneration of retinal ganglion cells and glial cell activation occur before development of retinal vasculopathy and are important early steps involved in the pathogenesis of DR (4). Glial cell activation triggers inflammation and oxidative stress, which in turn worsens DR. In the publication by Ding et al. , retinal glia was targeted to limit retinal neuronal degeneration from DR (5). Muller cells are the principal retinal glial cells that stretch across the thickness of the retina and provide homeostatic and metabolic support to neurons by mediating transcellular ion, water and bicarbonate transport (6). They are components of the neurovascular unit in the retina, regulating the blood-retinal barrier and synaptic activity of retinal neurons. Microglia are resident immune cells contributing to immune surveillance. Microglia, activated by retinal injury, produce proinflammatory mediators and kill degenerating retinal neurons (7). Targeting the retinal glia to limit retinal damage from DR is a novel, logical approach. Ding et al. used a rat model of DR to study the effect of inhibition of nuclear factor-κB (NF-κB) activation via systemic administration of IMD-0354 (5) since NF-κB is a transcription factor that regulates the activation of microglia and Muller cells (8). In addition, in vitro studies were conducted using cultured retinal glial cells to evaluate the effects of IMD-0354. The authors found that the increase in nuclear NF-κB-p65 associated with DR was reduced by IMD-0354 administration. IMD-0354 also inhibited microglia and Muller cell activation and oxidative damage and apoptosis of the retinal neurons associated with DR. Decreased retinal production of VEGF and inflammatory cytokines was also observed. In vitro studies similarly showed that IMD-0354 inhibited the molecular changes associated with high glucose in cultured Muller cells and microglia. The study findings are compelling although many questions remain unanswered. What are long-term effects of inhibiting NF-κB activation on retinal function and development of DR? Since NF-κB is ubiquitously expressed, is systemic inhibition of this factor well tolerated? Since the pathogenesis of DR is complex, further investigation is needed regarding the role of NF-κB and glia in the development of DR. Funding: This work was supported in part by the Barbara A. & Alan M. Roth, MD Endowed Chair of Discovery, Education and Patient Care in Vision Science (SS Park) from the University of California Davis. Provenance and Peer Review: This article was commissioned by the editorial office, Annals of Translational Medicine . The article did not undergo external peer review. Conflicts of Interest: The author has completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-1166/coif). The author reports contracted research to employer for multicenter clinical trial from industry evaluating intravitreal drugs that inhibit VEGF or inflammation to treat retinopathy. The author has no other conflicts of interest to declare. Ethical Statement: The author is accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replica -Abstract Truncated-

Enhancing Fractalkine/cx3cr1 Signalling Pathway Can Reduce Neuroinflammation by Attenuating Microglia Activation in Experimental Diabetic Retinopathy

Fractalkine isoforms differentially regulate microglia-mediated inflammation and enhance visual function in the diabetic retina

Fractalkine signaling during systemic endotoxemia inhibits perivascular microglial lesion formation in the diabetic retina

Therapeutic Delivery of Soluble Fractalkine Ameliorates Vascular Dysfunction in the Diabetic Retina

Crocin Inhibits Oxidative Stress and Pro-inflammatory Response of Microglial Cells Associated with Diabetic Retinopathy Through the Activation of PI3K/Akt Signaling Pathway

Retinal glia and NF-κB in diabetic retinopathy pathogenesis

Inhibition of NF-κB ameliorates aberrant retinal glia activation and inflammatory responses in streptozotocin-induced diabetic rats

Curcumin Suppresses Oxidative Stress Via Regulation of ROS/NF-κB Signaling Pathway to Protect Retinal Vascular Endothelial Cell in Diabetic Retinopathy

Pharmacological depletion of microglia alleviates neuronal and vascular damage in the diabetic CX3CR1-WT retina but not in CX3CR1-KO or hCX3CR1I249/M280-expressing retina

FKN/NR Signaling Pathway Regulates Hippocampal Inflammatory Responses: the Survival of Hippocampal Neurons in Diabetic Rats with Chronic Unpredictable Mild Stress

Microglia-endothelial cross-talk regulates diabetes-induced retinal vascular dysfunction through remodeling inflammatory microenvironment

Fenofibrate ameliorates diabetic retinopathy by modulating Nrf2 signaling and NLRP3 inflammasome activation

Natural Flavonoid Galangin Alleviates Microglia-Trigged Blood-Retinal Barrier Dysfunction During the Development of Diabetic Retinopathy.

A New Modulator of Neuroinflammation in Diabetic Retinopathy: USP25

325-OR: Glucagon-Like Peptide 1 Receptor Agonists Preserved Vascular Endothelial Junction through Inhibition of STING Signaling–Elicited Inflammation in Diabetic Retinopathy

Dysregulated CD200-CD200R signaling in early diabetes modulates microglia-mediated retinopathy

Redox Regulation of Immunometabolism in Microglia Underpinning Diabetic Retinopathy

Mechanistic insights into the alterations and regulation of the AKT signaling pathway in diabetic retinopathy

VEGF promotes diabetic retinopathy by upregulating the PKC/ET/NF-κB/ICAM-1 signaling pathway

Protective effects of nattokinase against microvasculopathy and neuroinflammation in diabetic retinopathy